GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (STU:49B) » Definitions » EV-to-EBITDA

BeOne Medicines (STU:49B) EV-to-EBITDA : -219.59 (As of May. 31, 2025)


View and export this data going back to 2018. Start your Free Trial

What is BeOne Medicines EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, BeOne Medicines's enterprise value is €23,665 Mil. BeOne Medicines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was €-108 Mil. Therefore, BeOne Medicines's EV-to-EBITDA for today is -219.59.

The historical rank and industry rank for BeOne Medicines's EV-to-EBITDA or its related term are showing as below:

STU:49B' s EV-to-EBITDA Range Over the Past 10 Years
Min: -231.08   Med: -12.32   Max: -4.2
Current: -228.22

During the past 12 years, the highest EV-to-EBITDA of BeOne Medicines was -4.20. The lowest was -231.08. And the median was -12.32.

STU:49B's EV-to-EBITDA is ranked worse than
100% of 497 companies
in the Biotechnology industry
Industry Median: 8.25 vs STU:49B: -228.22

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-05-31), BeOne Medicines's stock price is €17.17. BeOne Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was €-0.270. Therefore, BeOne Medicines's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


BeOne Medicines EV-to-EBITDA Historical Data

The historical data trend for BeOne Medicines's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines EV-to-EBITDA Chart

BeOne Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.04 -15.73 -11.03 -14.78 -45.73

BeOne Medicines Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.54 -17.19 -30.58 -45.73 -239.19

Competitive Comparison of BeOne Medicines's EV-to-EBITDA

For the Biotechnology subindustry, BeOne Medicines's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's EV-to-EBITDA falls into.


;
;

BeOne Medicines EV-to-EBITDA Calculation

BeOne Medicines's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=23664.706/-107.77
=-219.59

BeOne Medicines's current Enterprise Value is €23,665 Mil.
BeOne Medicines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-108 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeOne Medicines  (STU:49B) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BeOne Medicines's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=17.17/-0.270
=At Loss

BeOne Medicines's share price for today is €17.17.
BeOne Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.270.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


BeOne Medicines EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BeOne Medicines Business Description

Address
c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeOne Medicines Headlines

No Headlines